SFA Therapeutics
PrivateLast Round
Series A
Mar 13, 2025
Est. Valuation
$250M
Total Funding Raised
$4.23M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
SFA Therapeutics is a clinical-stage biopharmaceutical company that develops oral, small-molecule therapeutics for autoimmune diseases, chronic inflammatory diseases, and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SFA Therapeutics Comparables
Compare SFA Therapeutics with similar companies based on industry and business-model similarity.
SFA Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 13, 2025 | ||||
| VC Round | Nov 9, 2023 | ||||
| Seed | Jun 20, 2022 | ||||
| Accelerator | Sep 2, 2021 | ||||
| Grant | Jun 24, 2020 | ||||
Seed | Jul 31, 2018 |
Key People
Founding team and executive leadership
SFA Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| INP Capital | Seed |
| Benjamin Franklin Technology Partners | Seed, VC Round, Grant |
| Acequia Capital | Seed |
| Asymmetry Ventures | Seed, VC Round |
| Y Combinator | Accelerator |
| Montgomery County, Pennsylvania | Seed, VC Round, Grant |
| Boost VC | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 465% MoM.
- Apr 17, 2026
Monthly visitors increased 44% MoM.
Recent news
Latest coverage and updates
- promotesAug 19, 2026
SFA Therapeutics, Inc. promoted Ira C. Spector to Chief Strategy Officer on Aug 19th '26.
- hiresAug 19, 2026
SFA Therapeutics, Inc. hired Shawn Patrick O'Brien as CEO on Aug 19th '26.
SFA Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about SFA Therapeutics's valuation, stock price, and market status.
Is SFA Therapeutics a public or private company?
SFA Therapeutics is a private company.
What is the current stock price of SFA Therapeutics?
SFA Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is SFA Therapeutics worth (valuation)?
SFA Therapeutics's valuation is estimated at $250.0M based on funding round data.
Can I buy SFA Therapeutics stock?
SFA Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was SFA Therapeutics's last funding round?
SFA Therapeutics's most recent funding round was Series A on March 13, 2025.
Who are the main investors in SFA Therapeutics?
Key investors in SFA Therapeutics include Acequia Capital, Y Combinator, North South Ventures.
Will SFA Therapeutics IPO soon?
No public IPO plans have been announced for SFA Therapeutics.
How can I track SFA Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor SFA Therapeutics's secondary market activity and sign up for updates.